Eiger BioPharmaceuticals (EIGR) Given Media Sentiment Rating of 0.11

Press coverage about Eiger BioPharmaceuticals (NASDAQ:EIGR) has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Eiger BioPharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.5128107576102 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news articles that may have impacted Accern’s analysis:

Shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) traded up 7.41% during midday trading on Friday, reaching $11.60. The company’s stock had a trading volume of 145,121 shares. The stock has a 50-day moving average price of $11.55 and a 200 day moving average price of $8.81. Eiger BioPharmaceuticals has a 52 week low of $6.10 and a 52 week high of $13.95. The stock’s market capitalization is $97.06 million.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last issued its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($1.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.05). Equities analysts forecast that Eiger BioPharmaceuticals will post ($5.20) earnings per share for the current year.

Several equities analysts recently weighed in on EIGR shares. BTIG Research started coverage on Eiger BioPharmaceuticals in a research report on Friday, July 14th. They set a “buy” rating and a $32.00 target price on the stock. Zacks Investment Research downgraded Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 26th. Wedbush reiterated an “ourperform” rating and set a $34.00 target price on shares of Eiger BioPharmaceuticals in a research report on Monday, August 14th. Piper Jaffray Companies reiterated a “buy” rating and set a $36.00 target price on shares of Eiger BioPharmaceuticals in a research report on Tuesday, August 15th. Finally, ValuEngine upgraded Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. Eiger BioPharmaceuticals has an average rating of “Buy” and a consensus target price of $30.43.

ILLEGAL ACTIVITY NOTICE: “Eiger BioPharmaceuticals (EIGR) Given Media Sentiment Rating of 0.11” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/28/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-eiger-biopharmaceuticals-eigr-stock-price.html.

In other Eiger BioPharmaceuticals news, Director Jeffrey S. Glenn bought 15,000 shares of the stock in a transaction dated Friday, September 1st. The shares were bought at an average cost of $9.53 per share, with a total value of $142,950.00. Following the completion of the acquisition, the director now owns 31,355 shares of the company’s stock, valued at $298,813.15. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 28.80% of the stock is currently owned by company insiders.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Insider Buying and Selling by Quarter for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply